Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.

Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.

Abstract: Anti-CTLA4 antibodies, anti-PD1 antibodies, mixtures thereof, polynucleotides encoding such antibodies or mixtures, optionally carried on vectors, and methods of treatment utilizing such antibodies, mixtures, polynucleotides, or vectors are described herein. The anti-CTLA4 and anti-PD1 antibodies have particular sequences and properties. The methods of treatment include uses in treatment of cancer, infections, and immunodeficiency disorders.

Abstract: Disclosed are methods for treating late stage (e.g., clinical stage III or IV), unresectable non-small-cell lung cancer (NSCLC) with an antibody that inhibits PD1/PD-L1 activity in a patient identified as having not progressed following definitive chemoradiation therapy.

Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.

Abstract: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.

Abstract: The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.

Abstract: Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.

Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The invention relates to polypeptides specifically binding to CD38 and are therefore suitable for the diagnosis and for the therapeutic and prophylactic treatment of diseases which are characterized by increased CD38 expression. Conjugates and pharmaceutical compositions comprising the polypeptides are disclosed as well. In addition, the invention relates to the use of such polypeptides in methods for the detection of CD38 and/or CD38-expressing cells in a biological sample. A process for the purification and concentration of CD38 and/or CD38-expressing cells in which the antigen-binding polypeptides are used are also described.

Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.

Abstract: Provided in the present invention is a bispecific antibody which comprises an antibody fragment of anti-MUC1 VHH and an antibody fragment of anti-CD16 VHH. The antibody fragment used in the present invention is a variable region sequence derived from a heavy chain camelid antibody and has a high binding affinity to the antigen. Antibody fragments recognizing MUC1 and CD16 are constructed in the same antibody molecule by the invention, so that the antibody molecule can specifically bind to MUC1 and CD16 molecules to promote the killing effect of NK cells on MUC1-positive expression cells and has an inhibiting effect on the growth of MUC1-positive tumors. Also provided is a conjugate of the bispecific antibodies, a related pharmaceutical composition and use.

Abstract: Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill TAG-72-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a TAG-72-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.

Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.

Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.

Abstract: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis. In certain embodiments, pairs of activating Tie-2 antibodies showed an additive effect on the treatment of influenza infection when combined with anti-influenza HA. In other embodiments, prophylactic administration pairs of activating Tie2 antibodies delayed death and improved survival in a lethal model of E. coli intoxication (sepsis) over isotype/untreated controls.

Abstract: Methods and combination therapies for treating, preventing, and/or delaying the onset and/or development of Alzheimer's disease using an anti-A? protofibril antibody (such as, for example, BAN2401) and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof (Compound X) are provided.

Abstract: An object of the present invention is to provide a fragment antibody which can be conveniently produced as one having antigen-binding activity, and which has a greater ability to crystallize itself alone or as a complex with an antigen molecule than that of Fv-clasp (v1) even in a case where the fragment antibody is obtained in an E. coli expression system. The present invention relates to a fragment antibody including a complex of a peptide (VH(112C)-SARAH) in which an N-terminus of a SARAH domain is linked to a C-terminus of a heavy chain domain (VH region) of an antibody, and an amino acid residue of antibody residue 112 according to Chothia numbering scheme in the VH region is mutated to cysteine; and a peptide (VL-SARAH(37C)) in which an N-terminus of a SARAH domain is linked to a C-terminus of a light chain domain (VL region) of an antibody, and an amino acid residue at position 13 from the C-terminus in the SARAH domain is mutated to cysteine.

Abstract: The invention relates to the separation of manure in fractions and the treatment of said fractions in order to retrieve useful components to produce manure-derived bioplastic and other manure-derived bioproducts. The invention further relates to a method for producing composite (bio)plastic, and to a method for producing fibre from regenerated manure-derived cellulose. The methods include the steps of: flocculation treatment and a filtration treatment; pulping the manure-derived solid fractions; acetylation of the manure-derived dissolving-grade cellulose pulp with acetic anhydride and a catalyst; extracting fermentable components from the different fractions of the manure to produce monocarboxylic acids for use in the monocarboxylic acid carrier solution. Furthermore methods are disclosed for forming composite bioplastics with resin binding agents; and for spinning yarn from cellulose pulp.

Abstract: A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.

Abstract: This disclosure relates to carboxylated spherical crystalline chitin nanoparticles (SChNPs) having an average diameter of about 18-20 nm or less; and a process for producing same from the chitinous material, comprising contacting a chitinous material with an Oxone monopersulfate reagent (Formula (II)). (KHSO5.0.5KHSO4.0.

Abstract: Sulfur functionalized polyalphaolefins (PAOs) comprising at least one —S—CH2—C(R1R2)—S— moiety, wherein R1 and R2 are independently selected from linear or branched alkyl, are provided. The sulfur functionalized polyalphaolefins (PAOs) are prepared by contacting PAO with elemental sulfur and are useful as lubricating oil base stocks or co-base stocks. The sulfur functionalized PAOs exhibit high oxidative stability and can be prepared without the need for hydrogenation.

Abstract: A gas-phase process for the homopolymerization or copolymerization of olefins carried out in the presence of a catalyst system formed by a contacting, in a liquid hydrocarbon and in the presence of hydrogen, (a) a solid catalyst component comprising Ti, Mg, and Cl, and optionally an internal electron donor compound, (b) an aluminum alkyl compound and optionally (c) an external donor compound.

Abstract: The invention relates to a biaxially oriented polypropylene (BOPP) film comprising a propylene homopolymer or propylene-ethylene copolymer having an ethylene content of at most 1.0 wt % based on the propylene-ethylene copolymer having an Mw/Mn in the range from 5.0 to 12, wherein Mw stands for the weight average molecular weight and Mn stands for the number average weight and wherein Mw and Mn are measured according to ASTM D6474-12, an XS in the range from 1.0 to 6.0 wt %, wherein XS stands for the amount of xylene solubles which are measured according to ASTM D 5492-10, a melt flow rate in the range of 1 to 10 dg/min as measured according to IS01133 (2.16 kg/230° C.) and a crystal size distribution as indicated by a height/width ratio of the highest peak of the first cooling curve of at least 0.70 W/g° C. as determined by ASTM D3418-08 using a heating and cooling rate of 10° C./min.

Abstract: An acrylic acid polymer having a weight average molecular weight Mw in the range from 3500 to 2000 g/mol and a polydispersity index Mw/Mn?2.5, wherein 30% to 60% of the acid groups of the acrylic acid polymers have been neutralized with calcium ions, 30% to 70% of the acrylic acid polymers have been neutralized with sodium ions and 0% to 10% of the acid groups of the acrylic acid polymers have not been neutralized.

Abstract: The present invention relates to a process for the production of polyacrylonitrile by polymerisation of a reaction mixture comprising acrylonitrile in a solution where the solvent is a eutectic system comprising a quaternary ammonium compound and a hydrogen donor. Such process allows for the production of a polyacrylonitrile having a desirably high molecular weight, whilst polymerisation time is reduced, and where the solvents are environmentally benign, biodegradable and may be reused in the polymerisation process.

Abstract: Methods are described for the preparation of polymers using a lanthanide-based coordination catalyst and arresting polymerization using a reduced amount of a Lewis base while retaining the reactivity of the polymer chain ends toward functionalization agents. The Lewis base is a meso-enriched oxolanyl Lewis base. The resulting functionalized polymer has a higher level of purity and can be used in products such as tires.

Abstract: The present invention relates to nucleated propylene-butylene copolymers comprising propylene and butylene monomer units, wherein the nucleated propylene-butylene copolymer has improved stiffness, better impact behaviour and optical properties such as low haze and improved optomechanical ability.

Abstract: The present disclosure provides methods for producing an olefin polymer including: i) contacting alpha-olefin with a first catalyst system comprising a first non-metallocene catalyst, a first activator, and a reversible chain transfer agent to form a first polymer; ii) contacting the first polymer with a coupling agent in the presence of a catalyst, an activator; and iii) obtaining a second polymer. The present disclosure further provides polymers having a g?vis value from about 0.4 to about 0.8 and a vinyl unsaturation content of 0.8 or greater vinyls/1000 carbons, and preferably low gel content.

Abstract: Embodiments of the present disclosure are directed to multimodal elastomers produced by olefin polymerization with a mixed catalyst system, specifically, a constrained geometry catalyst and a biphenyl phenol catalyst. The multimodal elastomers may be incorporated as impact modifiers in thermoplastic olefins.

Abstract: A crosslinkable surfactant useful for preparing an emulsion polymerization composition; the crosslinkable surfactant including (a) a crosslinkable functionality and a hydrophobic tail with a Tung oil derivative structure, and (b) a polyalkylene oxide or polyglycerin part as hydrophilic head; an emulsion polymerization process using the crosslinkable surfactant; an emulsion polymerization composition; and a process for preparing the emulsion polymerization composition.

Abstract: By a method for producing a resin, a resin containing a repeating unit represented by General Formula (1) and a repeating unit containing a group that decomposes by the action of an acid to generate a polar group is produced, and the method includes a first step of obtaining a resin precursor containing a repeating unit represented by General Formula (2) and the repeating unit containing a group that decomposes by the action of an acid to generate a polar group, and a second step of obtaining the repeating unit represented by General Formula (1) by deprotecting a group represented by —OY in the repeating unit represented by General Formula (2) in the resin precursor with an acid or a base.

Abstract: Adhesive compositions that are optically transparent include a (meth)acrylate-based copolymer having a refractive index of at least 1.48, and particles of a thermoplastic polymer. At least some of the particles have an average particle size that is larger than the wavelength of visible light. The adhesive compositions are prepared by hot melt processing packaged adhesive compositions.

Abstract: A synthetic polymer film has a surface which has a plurality of raised portions, wherein when viewed in a normal direction of the synthetic polymer film, a two-dimensional size of the plurality of raised portions is in the range of more than 20 nm and less than 500 nm, the synthetic polymer film is made of a curable resin which contains a first polymerizable fluoric compound, the first polymerizable fluoric compound containing a fluorine element, the first polymerizable fluoric compound has a plurality of polymerizable functional groups and has a molecular weight of not less than 1000 and not more than 5000, and at the lapse of 5 minutes since placing a 200 ?L drop of water on the surface of the synthetic polymer film, a pH of an aqueous solution is not less than 6.5 and not more than 7.5.

Abstract: A polymer composition includes a first host polymer, which is a copolymer of (meth)acrylamide and at least one cationic first monomer, and a second polymer, which is a copolymer of (meth)acrylamide and at least one cationic second monomer. The second polymer is polymerised in presence of the first host polymer, and the first host polymer has a higher cationicity than the second polymer, the difference in cationicity of the first host polymer and the second polymer being at least 3 mol-%, at least 5 mol-%, more preferably at least 7 mol-%. The polymer composition has a standard viscosity of >2.0 mPas, measured at 0.1 weight-% solids content in an aqueous NaCl solution (1 M), at 25° C., using Brookfield VII T viscometer with UL adapter. The invention relates also to uses of said polymer composition.

Abstract: A method of producing dimethoxymethane oligomers (DMMn), the method comprising: reacting a formaldehyde source and dimethoxymethane monomer (DMM1) in the presence of an acidic catalyst to produce a reaction effluent comprising DMMn and unreacted DMM1; and separating, from the reaction effluent, DMM1-2 including unreacted DMM1 and DMMn having a chain length n equal to 2 (DMM2), dimethoxymethane oligomers having a chain length n in the range of from 2-5 (DMM2-5), dimethoxymethane oligomers having a chain length n of ?5 (DMM5+), or a combination thereof, wherein the separating comprises distillation in the presence of at least one alcohol, a distillate fuel, or both.

Abstract: Disclosed herein is an aerogel made from a polyhydroxy benzene compound crosslinked with formaldehyde. The aerogel is dry and has a first volume and wherein the aerogel can be exposed to a liquid and be re-dried in a gas while retaining at least 70% of the first volume.

Abstract: A polyurethane resin having an anionic group and a polyalkylene oxide in a side chain thereof is obtainable by reacting a polyester polyol, a polyether diol, a polyol containing an anionic group, and a polyisocyanate, and the polyester polyol is obtained by reacting an aromatic polycarboxylic acid and a polyol. The polyurethane resin can be used as binder in an ink jet ink and provides excellent scratch and solvent resistance of printed images.

Abstract: The present invention relates to a method of preparing a polyurethane elastomer, said method comprising the step of reacting at least one isocyanate composition (ZI) and one polyol composition (ZP) comprising a poly-?-caprolactone polyol and an ?-hydro-?-hydroxy-poly(oxytetramethylene) polyol to obtain an isocyanate-functional prepolymer and the step of reacting the prepolymer obtained as per step (i) with at least one chain extender (KV). The present invention further relates to a polyurethane elastomer obtained or obtainable according to a method of the invention and also to the method of using a polyurethane elastomer according to the invention or a polyurethane elastomer obtained or obtainable according to a method of the invention in the manufacture of a shaped article, especially a damping element, a shock absorber or a stop buffer or part of a shoe or of a shoe sole, for example part of an insert sole or of a midsole.

Abstract: A functionalized polyurethane polymer is provided, the polymer defined by the formula where each R? is independently derived from a diisocyanate, where each R? represents the soft segment of the polymer, where n is the number of repeat units within the soft segment of the polymer, where m is the number of repeating mer units in the polymer, where each E is a pendant-functionalized amide unit chain extender, wherein the nitrogen atom of the amide group is part of the polymer backbone. A method for preparing the polymer is also provided.

Abstract: The present disclosure is drawn to a reactive polyurethane dispersion including a polymer strand having a polymer backbone that has two ends terminating at a first capping unit and a second capping unit. The polymer backbone can include polymerized monomers including a reactive diol and a diisocyanate. The reactive diol can be an acrylate-containing diol, a methacrylate-containing diol, an allyl-containing diol, or combination thereof. The first capping unit can be an allyl-containing monoalcohol reacted with an isocyanate group of the diisocyanate. The second capping unit can be an ionic stabilizing group.

Abstract: Provided is a resin composition that can provide a cured product of low dielectric tangent, high mechanical strength, and high adhesiveness. The resin composition contains (A) a resin having a thermosetting functional group FA, (B) a resin having a radical polymerizable functional group FB, and (C) a resin having a functional group FA? reacting with the thermosetting functional group FA and a functional group FB? reacting with the radical polymerizable functional group FB. A number na of the functional group FA? of the component (C) when the number of the thermosetting functional group FA of the component (A) is defined as 1 and a number nb of the functional group FB? of the component (C) when the number of the radical polymerizable functional group FB of the component (B) is defined as 1 satisfy 0.01?na?200 and 0.01?nb?400, respectively.

Abstract: A high heat epoxy composite including a substrate; a matrix composition comprising: a high heat epoxy compound, and a hardener, wherein the matrix composition comprises 20 to 40 total weight percent of the composite; and wherein a cured sample of the matrix composition has a glass transition temperature of greater than or equal to 200 C; and a cured, laminated sample of the composite has a flexural strength of greater than 850 MPa measured as per ASTM D7264; and a flexural modulus of greater than 65 GPa measured as per ASTM D7264 is provided.

Abstract: The present application relates to a curable composition. The curable composition of the present application exhibits excellent adhesion ability and liquid crystal orientation ability simultaneously before or after curing, so that it can be effectively applied to various optical uses.

Abstract: A composition including a polythiol having more than one thiol groups, a polyepoxide having more than one epoxide group, a photolatent base catalyst that can photochemically generate a first amine, and a second amine phase-separated within the composition. A polymer network preparable from the composition, and a method for making the polymer network are also disclosed.

Abstract: Polyester compositions are disclosed herein, as well as methods of making and using such polyesters. In some embodiments, the polyesters are formed from monomers derived from natural oils. In some embodiments, the polyesters are highly branched polymers, such as highly branched polymers that have low viscosity at higher molecular weights.